Zynga Inc (NASDAQ:ZNGA), issued an update on its FY14 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.01-0.03 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.02, American Banking News reports. Zynga also updated its Q2 guidance to $0.00-0.01 EPS. Zynga Inc (NASDAQ:ZNGA), shares after opening at $4.64 moved to $4.66 on last trade day and at the end of the day closed at $4.35. Company price to sales ratio in past twelve months was calculated as 4.37 and price to cash ratio as 3.39. Zynga Inc (NASDAQ:ZNGA), showed a positive weekly performance of 5.84%.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s shares dropped 2.38% to $20.55. The company presented at the 13th Annual Needham Healthcare Conference on April 8, 2014, at 8:40 a.m. Eastern Time in New York City. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), shares advanced 2.04% in last trading session and ended the day on $20.55. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), return on equity ratio is recorded as -24.30% and its return on assets is -21.70%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), yearly performance is 52.22%.
On April 24, 2014, CARBO Ceramics Inc. (NYSE:CRR), reported net income of $18.4 million, or $0.80 per share, on revenues of $148.6 million for the quarter ended March 31, 2014. CARBO Ceramics Inc. (NYSE:CRR), shares moved down 0.40% in last trading session and was closed at $136.66, while trading in range of $ 124.58 – 144.35. CARBO Ceramics Inc. (NYSE:CRR), year to date (YTD) performance is 17.61%.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), saw unusually-strong trading volume on Friday following insider buying activity,American Banking News reports. Approximately 1,170,831 shares traded hands during mid-day trading, an increase of 57% from the previous session’s volume of 745,942 shares.The stock last traded at $61.24 and had previously closed at $65.13. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), weekly performance is -3.35%. On last trading day company shares ended up $52.78. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), distance from 50-day simple moving average (SMA50) is -25.34%. Analysts mean target Price for the company is $101.00.